Deroma, a Njord Partners Portfolio Company, Appoints New CEO
27.3.2024 11:00:00 EET | Business Wire | Press release
Deroma, the world’s largest Terracotta producer, together with Njord Partners, today announce the appointment of Stefano Mele as CEO of Deroma, effective from 4 March 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327185499/en/
Stefano is a highly experienced business leader in Italy, focused on the manufacturing and industrial sectors where he has a track record of delivering successful growth strategies. Stefano’s diverse background spans various sectors, from textiles and ceramics to machines and printing. As a proven leader, he has held key roles as CEO and Managing Director in international companies and business units.
Stefano has most recently been CEO of Ceramica Dolomite, an Italian bathroom sanitaryware manufacturer specialized in ceramics with 360 employees. In less than two years, he has transformed the company, which was earmarked for closure, by relaunching the commercial production of the company, creating 7 new product series in one year and developing collaboration with other sanitaryware manufacturers to facilitate reshoring their production. Before this, Stefano was CEO of Fabbri Group, an Italian fresh food packaging designer and producer.
Stefano’s multi-lingual skills and extensive international experience spanning Europe, North and South America, India and China will be invaluable for Deroma’s global expansion.
Stefano Mele, incoming CEO, commented: “I am excited to join Deroma as CEO. I hope to use my proven leadership skills and industry expertise to drive the next phase of Deroma’s growth, working together with the whole Deroma team to produce outstanding products based on the legacy of craftmanship developed over almost 70 years. I look forward to working closely with Njord Partners to deliver on this incredible opportunity.”
Arvid Trolle, Partner at Njord Partners, said: “Stefano is a world-class leader and he will be instrumental in our exciting plans to double the size of the business and further expand globally. Stefano’s experience across the wider ceramics industry will enable Deroma to fuel the gardening passion of millions of people with the continued pursuit of the highest quality Terracotta, plastic and glazed pots.”
About Stefano Mele
Stefano began his career in 1990 as a Project Engineer at Alcatel. He went on to hold management positions at Nuova Fima, Viappiani Printong, SIAT and GEA Group. Most recently, he was CEO of Fabbri Group (2019-2022) where he achieved double-digit increases in both turnover and EBITDA through entering new markets and launching a new range of environmentally sustainable products and integrated software solutions. Since 2022, Stefano has been the CEO of Ceramica Dolomite where he has relaunched their commercial production, creating seven new product series in less than two years.
About Deroma
Deroma Group is the largest Terracotta producer globally and is headquartered in Italy. Deroma produces in Europe and the United States and operates globally, with recent expansion in the UK, Asia Pacific and Eastern Europe. As a global leader in high-end garden products, Deroma also designs and distributes pots and vases made of plastic, glazed and other materials. Deroma was successfully acquired by Njord Partners in June 2021.
To find out more visit: https://deroma.com
About Njord Partners
Njord Partners is a special situations investment manager and provider of long-term flexible capital solutions. Established in 2013, Njord Partners manages capital in excess of €1 billion. Investing in European middle-market companies facing complex situations. Its mission is to deliver superior risk-weighted returns to investors while preserving capital. As a capital partner, Njord Partners offers flexible debt and equity solutions, actively facilitating strategic and operational enhancements within its portfolio companies to drive value, with a particular focus on existing debt securities and structures.
To find out more visit: https://njordpartners.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327185499/en/
Contact information
Media enquiries:
via Camarco
njord@apcoworldwide.com
Jennifer Renwick +44 7928 471 013
Letaba Rimell +44 7715 530 664
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom